) recently announced that the company has launched ACCELERATOR
a3600 - its next-generation track system to increase efficiency
A laboratory automation track system, ACCELERATOR a3600
enables processing for up to 3,600 samples per hour along with
handling multiple tube sizes and types simultaneously.
Moreover, this system automates routine, manual tasks which in
turn should lead to reduction in error and improvement in
efficiency. Further, automation helps laboratories around the
world to cope with staffing shortages, budget constraints, and
Abbott Labs developed ACCELERATOR a3600 with its Swiss partner
Inpeco SA to address the growing need for faster processing in
tests while handling increased volume.
We note that the diagnostics business is one of the key
businesses for Abbott Labs after having separated its proprietary
pharmaceutical business into a new company called
) on Jan 1, 2013.
Abbott Labs continues to focus on the development of
next-generation instruments and other advanced technologies along
with expansion in emerging markets in its diagnostics business.
In particular, improvement in operating margins is a key area of
emphasis in this segment.
A few days ago, Abbott Labs announced that the company
obtained CE Marking (Conformite Europeenne) for its ARCHITECT
Galectin-3 assay test. The CE mark is mandatory confirmation for
products placed in the European markets. Abbott developed this
test in collaboration with
BG Medicine, Inc.
) to run on its ARCHITECT immunochemistry platform.
The test is primarily aimed to enable doctors in assessing the
prognosis of patients diagnosed with chronic heart failure (HF).
ARCHITECT Galectin-3 assay test is available in several European
Galectin-3 can indicate heart failure by chalking out the
pathophysiology of HF. Subsequently, the doctors can identify the
susceptible patients for heart failure who are at high risk.
We believe that Abbott Labs is extremely diversified with a
presence in the nutrition, diagnostics, generic pharmaceuticals
and medical devices markets. In particular, the nutrition and
diagnostics business should maintain momentum and boost the
bottom line due to an improvement in operating margins.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
) currently looks attractive with a Zacks Rank #1 (Strong
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BG MEDICINE INC (BGMD): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
To read this article on Zacks.com click here.